TraceLink breaks new record for highest quarterly sales bookings in Q2 2017
Company also becomes the first solution provider to achieve 100 pharmaceutical and contract manufacturers live and ready for serialization.
TraceLink has announced financial and company results for the second quarter of 2017.
Growth highlights for the second quarter of 2017 include
- 42% representing pharmaceutical and contract manufacturers
- 7% representing wholesale distributors
- 51% representing pharmacies, hospitals and health systems, covering more than 4,200 US dispensing locations.
“I am extremely proud of our global team for achieving our highest new quarterly sales bookings ever, hitting an all-time record for the company,” said Shabbir Dahod, president and CEO, TraceLink. “Since track and trace regulatory deadlines were enacted, TraceLink has experienced explosive year-over-year growth, validating the industry’s need for a proven, scalable network to meet their serialization needs. As the industry integrates serialization into day-to-day operations, the TraceLink network is the only solution capable of providing critical value-add services that leverage the sharing of real-time information for business insights that will improve patient outcomes.”
Additional Q2 2017 growth highlights and milestones include
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.